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ABSTRACT 
Introduction 
Incidence of neuroendocrine tumor (NET) is increased in the last thirty years from 1.1 to 5.2 cases 
per 100,000 people in the United States. They can originate from the pancreatic gland and for the 
majority of cases are not functioning (80%). A small percentage of functioning may produce 
adrenocorticotropic hormone (ACTH) and lead to ectopic ACTH Syndrome (EAS), responsible of 
Cushing-Syndrome. 
Results  
We present a case of a 30 year-old woman suffering from EAS due to a neoformation of the 
pancreatic tail of the maximum diameter of 4 cm. The lesion was resectable at preoperatory 
imaging. The patient was subjected to distal splenopancreasectomy. Histological examination 
showed a well-differentiated neuroendocrine carcinoma pT3N0. The postoperative course was 
regular. At two years of follow-up patient is almost completely asymptomatic for Cushing's but she 
has developed multiple liver metastases, for which she began chemotherapy. 
Discussion  
p-NET responsible for EAS is usually malignant and the radical treatment of excision of the lesion 
is not possible because they occur at the time of diagnosis with liver metastases or unresectable. 
Our patient had a mass at the time of diagnosis resectable but despite radical surgery, she has 
developed multiple liver metastases at two years and she was undergoing chemotherapy. 
Conclusions  
In agreement with previous literature we confirm the aggressive nature of pancreatic tumors 
secreting ACTH, despite radical surgery. Conversely, surgical treatment is effective on the 
resolution of clinical symptoms. 
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1. Introduction 
Cushing's syndrome caused by ectopic production of adrenocorticotropic hormone (ACTH or 
corticotropin) or EAS (Ectopic ACTH Syndrome) is responsible for 10–20% of Cushing's 
syndrome cases in the west countries [1] and 3.6% of cases in Japan [2]. Small cell lung carcinoma 
is the first cause of EAS, it is responsible of approximately 50% of all the tumors; other causes are 
indolent tumors as bronchial and thymic tumors, thyroid medullary carcinoma and 
gastroenteropathic neuroendocrine tumors (GEP-NET). 
A dramatic increase was reported in neuroendocrine tumors incidence from 1.1 to 5.2 cases per 
100,000 people, age-adjusted to the US population between 1973 and 2004 [3]. 
Such increase presumably depends on a few factors, including a more precise NET classification, 
endoscopy diffusion for tumors screening and other more sensitive imaging techniques as 
echoendoscopy and computerized tomography (CT) [4]. Regarding pancreatic NETs (pNET), 
incidence is 0.32 cases per 100,000 people per year, lower than lung, ileum and rectum NETs 
incidence (respectively 1.35, 0.67, 0.86, per 100,000). However, autopsic incidence of pNETs is 
higher (1.5% per year): this means that a considerable group of these tumors is underdiagnosed [5]. 
PNETs are classified as functioning (F-) and non-functioning (NF-), depending on the presence or 
not of an accompanying hormonal syndrome. NF-pNETs represent the majority of pNETs (60–
80%). Insulinoma and gastrinoma are the most frequent (respectively 17 and 15%) among 
functioning pNETs; glucagonoma (1%), VIPoma (2%) and somatostatinoma (<1%) are less 
common [6]. There also exist other tumors producing ectopic hormone such as ACTH (1.2%) [7]. 
These pNETs are generally malignant except for insulinoma. The European Neuroendocrine Tumor 
Society (ENETS) and the World Health Organization (WHO) have suggested a strategy for the 
diagnosis and treatment of NETs. WHO has suggested the classification of NEs according to 
criteria such as the presence of metastases, the Ki-67/MIB-1 index, the histological grade, the 
vascular invasion and the tumor size [8]. The WHO classification of NETs includes: 1) well-
differentiated NETs (benign or with an undefined biological behavior), 2) well-differentiated 
neuroendocrine carcinomas 3) poorly-differentiated neuroendocrine carcinomas. ENETS 
classification places NETs in three groups: G1, G2, G3, also according to the Ki-67/MIB-1 index 
and number of nuclear mitosis, as well as the TNM classification of large intestine NETs [9] and 
[10]. The EAS deriving from an ACTH -secreting pNET is a particularly aggressive disease, where 
metastases are observed in the initial phases of the clinical progress, even before the development of 
Cushing's syndrome clinical symptoms [11]. In patients with this type of pNET the two-year 
survival rate was 40% and the five-year survival rate was 16% [12]. Indications for surgical therapy 
in presence of pNET are to relieve symptoms caused by hormonal excess in patients with 
functioning tumors and to alleviate obstructive and constitutional symptoms in patients with non-
functioning tumors. 
Even though enucleation and distal pancreatectomy are the appropriate surgical options in many 
cases, pancreatoduodenectomy could be necessary in larger size tumors or in tumors that involve 
the periampullary region [13]. 
In this study, we report the case of a female patient who developed EAS due to a pNET. 
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1.1. Case report 
We present the case of a 30 year old female patient, recovered in our ward after recovery in a 
medical area for suspect Cushing's syndrome due to ectopic production of ACTH. 
The patient had been suffering from asthenia, face hypertrichosis and declive edemas for three 
months. The anamnesis reported a hospitalization for bleeding duodenal ulcer. A Cushingoid 
phenotype is described at entrance, showing BMI 27.4, moon facies, face hypertrichosis, striae 
rubra on the abdomen, arterial hypertension (160/100 mm Hg). Having suspected 
hypercholesterolemia, ACTH was dosed (79.5 pg/ml). 
Upper abdomen CT was performed on patient and multiple hypodense formations, showing margins 
of the anterior surface of pancreas tail clear and partially confluent, were identified between the 
greater curvature of the stomach and the medial part of the spleen. Total body and segmentary 
scintigraphy using labeled Octreotide identified a weak extraphysiologic accumulation of the 
indicator in correspondence to the lesion shown by the CT. Abdomen echography confirms the 
presence of pancreas lesion, in absence of hepatic metastases. The patient completed the diagnostic 
procedure with hypophysis NMR with contrast medium (standard) and abdomen NMR, the latter 
describes thickening of the pancreatic tail due to a solid neoformation of 4 cm maximum diameter, 
indivisible from multiple formations of cystic aspect with thickened walls. The maximum global 
diameter of the wound is 10 cm. 
The patient was therefore subjected to an operation of distal laparotomic splenopancreasectomy. 
Surgical picture does not highlight hepatic lesions, nor signs of peritoneal carcinosis. Neoproducing 
lesion, that is removed, is exhibited at pancreas level. The surgical specimen includes the tail of the 
pancreas measuring 8×5×3cm in association with a cystic formation of 10×4×4cm adjacent to the 
spleen of 4×8cm and of 150g. At pancreatic parenchyma level adjacent to cystic formation it is a 
yellowish neoformation of 4.5cm maximum of diameter that is distant 5cm from the pancreatic 
resection edge and that appears contiguous to the spleenic parenchyma without macroscopic 
evidence of direct invasion. Histological examination identified in pancreatic parenchyma a well-
differentiated neuroendocrine carcinoma, with cystic component and focal extension to 
peripancreatic adipose tissue; mitosis 6/10 HPF, necrosis absent; extended angioinvasion; Ki67 
23% (high proliferative index). The spleen appears congested, adherent but not infiltrated by 
neoplastic mass. 
ENETS grading turned out to be G3, the stage pT3N0. 
Neoplastic cell typing turned out to be pervasively positive to Chromogranin and focally positive to 
ACTH. 
The patient was discharged on the 11th post-operative day. Upon discharge the patient is 
asymptomatic, in an euthymic mood. 
After operation the patient hasn't undergone any adjuvant therapy. After two years in absence of 
symptoms, we attended Cushing's syndrome relapse with abdomen algia, asthenia and face 
hypertrichosis. 
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Abdominal TC shows: 7 hepatic lesions with a maximum diameter of 7.5 cm, most likely of a 
secondary nature. She underwent multiple TACE, which resulted ineffective. 
On March 2013 she started chemotherapy with Capecitabine and Temozolamide. 
 
2. Discussion 
pNETs rarely produce ACTH with Cushing's syndrome symptoms. pNETs that determine EAS 
represent less than 1.2% of all pNETs in the Japanese population [4] and around 3.6% of all causes 
of EAS [2]. EAS-pNETs are usually malignant and they often present themselves with hepatic 
metastases at the time of diagnosis [8]. Because of the rapid disease progression, EAS-pNETs 
prognosis is low. 
Usually pNETs affect more frequently female gender and localize in the head and body of the 
pancreas. 
On average they measure 4.6 cm (2.5–7) [14]. 
In many cases the source of ectopic secretion of ACTH remains hidden for several years, in spite of 
multiple attempts of tumor localization. Signs and symptoms include increase in weight, central 
obesity, asthenia, glucose intolerance and hypertension. All patients have high levels of plasmatic 
and urinary cortisol [15],[16],[17]and[18]. Optimal treatment consists in localization and surgical 
exeresis of the tumor. Unfortunately, pancreatic ACTH-secerning tumors often appear with non-
resectable hepatic metastases. Bilateral suprarenalectomy is often used with palliative intent to 
control symptoms of these patients [19]. 
The patient presented in the clinical case, even though not showing hepatic metastases during 
diagnosis, developed secondariness two years after surgical operation. Actual guide lines suggest 
chemotherapy as standard for metastatic NETs [9], although underlining that CT has a weak impact 
on patient survival rate, even if it obtains a good control of disease. 
 
3. Conclusion 
According to literature in our case we noticed a remission of endocrine symptoms after exeresis of 
tumoral mass. pNETs emerge as tumors characterized by marked biological aggressiveness. In our 
experience the disease represented itself with ACTH-secerning hepatic secondariness two years 
after diagnosis and after operation on primitive neoplasia. 
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